These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23597562)

  • 1. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties.
    Bono F; De Smet F; Herbert C; De Bock K; Georgiadou M; Fons P; Tjwa M; Alcouffe C; Ny A; Bianciotto M; Jonckx B; Murakami M; Lanahan AA; Michielsen C; Sibrac D; Dol-Gleizes F; Mazzone M; Zacchigna S; Herault JP; Fischer C; Rigon P; Ruiz de Almodovar C; Claes F; Blanc I; Poesen K; Zhang J; Segura I; Gueguen G; Bordes MF; Lambrechts D; Broussy R; van de Wouwer M; Michaux C; Shimada T; Jean I; Blacher S; Noel A; Motte P; Rom E; Rakic JM; Katsuma S; Schaeffer P; Yayon A; Van Schepdael A; Schwalbe H; Gervasio FL; Carmeliet G; Rozensky J; Dewerchin M; Simons M; Christopoulos A; Herbert JM; Carmeliet P
    Cancer Cell; 2013 Apr; 23(4):477-88. PubMed ID: 23597562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling.
    Herbert C; Schieborr U; Saxena K; Juraszek J; De Smet F; Alcouffe C; Bianciotto M; Saladino G; Sibrac D; Kudlinzki D; Sreeramulu S; Brown A; Rigon P; Herault JP; Lassalle G; Blundell TL; Rousseau F; Gils A; Schymkowitz J; Tompa P; Herbert JM; Carmeliet P; Gervasio FL; Schwalbe H; Bono F
    Cancer Cell; 2013 Apr; 23(4):489-501. PubMed ID: 23597563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling].
    Herbert C; Alcouffe C; Bono F
    Med Sci (Paris); 2013 Oct; 29(10):834-6. PubMed ID: 24148118
    [No Abstract]   [Full Text] [Related]  

  • 4. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
    Ronca R; Giacomini A; Rusnati M; Presta M
    Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-angiogenic and anti-tumor activity of synthetic phenylpropenone derivatives is mediated through the inhibition of receptor tyrosine kinases.
    Lee JS; Kang Y; Kim JT; Thapa D; Lee ES; Kim JA
    Eur J Pharmacol; 2012 Feb; 677(1-3):22-30. PubMed ID: 22200628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
    Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
    J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor vasculature is regulated by FGF/FGFR signaling-mediated angiogenesis and bone marrow-derived cell recruitment: this mechanism is inhibited by SSR128129E, the first allosteric antagonist of FGFRs.
    Fons P; Gueguen-Dorbes G; Herault JP; Geronimi F; Tuyaret J; Frédérique D; Schaeffer P; Volle-Challier C; Herbert JM; Bono F
    J Cell Physiol; 2015 Jan; 230(1):43-51. PubMed ID: 24760775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
    Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J
    Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.
    Ezzat S; Huang P; Dackiw A; Asa SL
    Clin Cancer Res; 2005 Feb; 11(3):1336-41. PubMed ID: 15709206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms.
    Auguste P; Gürsel DB; Lemière S; Reimers D; Cuevas P; Carceller F; Di Santo JP; Bikfalvi A
    Cancer Res; 2001 Feb; 61(4):1717-26. PubMed ID: 11245488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
    Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
    Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.
    Bello E; Colella G; Scarlato V; Oliva P; Berndt A; Valbusa G; Serra SC; D'Incalci M; Cavalletti E; Giavazzi R; Damia G; Camboni G
    Cancer Res; 2011 Feb; 71(4):1396-405. PubMed ID: 21212416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer.
    Brooks AN; Kilgour E; Smith PD
    Clin Cancer Res; 2012 Apr; 18(7):1855-62. PubMed ID: 22388515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
    Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
    Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
    Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
    Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.